Overview

Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer

Status:
Completed
Trial end date:
2012-10-25
Target enrollment:
Participant gender:
Summary
The Phase I part of the study will identify the doses of pazopanib and paclitaxel that can be administered safely in combination. The Phase II part of the study will not be progressed as documented in Protocol Amendment 01.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel